Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Changes in cardiac biomarkers with bortezomib treatment in patients with advanced cardiac amyloidosis. Am J Hematol 2015 Nov;90(11):E212-3 PMID: 26284951 PMCID: PMC4618044

Pubmed ID

26284951

DOI

10.1002/ajh.24176

Author List

Hussain AS, Hari P, Brazauskas R, Arce-Lara C, Pasquini M, Hamadani M, D'Souza A

Authors

Ruta Brazauskas PhD Associate Professor in the Institute for Health and Equity department at Medical College of Wisconsin
Anita D'Souza MD Assistant Professor in the Medicine department at Medical College of Wisconsin
Mehdi H. Hamadani MD Professor in the Medicine department at Medical College of Wisconsin
Parameswaran Hari MD Chief, Professor in the Medicine department at Medical College of Wisconsin
Marcelo C. Pasquini MD, MS Associate Professor in the Medicine department at Medical College of Wisconsin




Scopus

2-s2.0-84944536944   3 Citations

MESH terms used to index this publication - Major topics in bold

Adult
Aged
Aged, 80 and over
Amyloidosis
Antineoplastic Agents
Biomarkers
Bortezomib
Creatinine
Cyclophosphamide
Dexamethasone
Drug Therapy, Combination
Female
Humans
Male
Middle Aged
Myocardium
Natriuretic Peptide, Brain
Peptide Fragments
Prognosis
Severity of Illness Index
Troponin T
jenkins-FCD Prod-321 98992d628744e349846c2f62ac68f241d7e1ea70